

Hikma achieves B scores in Climate Change and Water Security in 2025 CDP assessment

London, 15 January 2026 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, announced that it has achieved B scores in both Climate Change and Water Security categories in the 2025 Carbon Disclosure Project (CDP) assessment, maintaining strong environmental performance as CDP's methodology continues to evolve.

Achieving B-level scores in both categories requires robust governance frameworks, reliable data systems, and measurable action across operations. The Water Security score represents significant progress from earlier reporting cycles, demonstrating Hikma's strengthened approach to managing this critical resource - particularly notable given that a significant portion of the Group's manufacturing footprint operates in water-scarce regions across the Middle East and North Africa.

"These results reflect Hikma's sustained commitment to environmental excellence," said Tim Brooks, VP Sustainability at Hikma. "Our progress in Water Security is particularly significant given the pharmaceutical sector's reliance on this essential resource. While we're proud of this achievement, we recognise there is more work ahead. We remain committed to continuous improvement in our environmental performance and to maintaining transparency with our stakeholders as we advance our sustainability goals."

Hikma has been reporting to CDP since 2010, demonstrating a long-standing commitment to environmental transparency and accountability.

– ENDS –

Enquiries

Hikma (Investors)

Susan Ringdal	+44 (0)20 7399 2760 / +44 (0)7776 477050
EVP, Strategic Planning and Global Affairs	
Guy Featherstone	+44 (0)20 3892 4389/ +44 (0)7795 896738
Director Investor Relations	

Hikma (Media)

FTI Consulting	
Ciara Martin	+44 (0)7779 775979

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping



bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com